SEC Company Response from Viridian Therapeutics, Inc.\DE (VRDN) (CIK 0001590750) (VRDN) — Dec 21, 2020
Viridian Therapeutics, Inc.\DE (VRDN) (CIK 0001590750)
Date: Dec. 21, 2020 · CIK: 0001590750 · Accession: 0001590750-20-000141
AI Filing Summary & Sentiment
File numbers found in text: 333-251367
Letter
Document
Miragen Therapeutics, Inc.
6200 Lookout Road
Boulder, CO 80301
(720) 643-5200
December 21, 2020
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Abby Adams
Re: Miragen Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-251367
Acceleration Request
Requested Date: Tuesday, December 22, 2020
Requested Time: 4:01 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Miragen Therapeutics, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to December 22, 2020, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Brent Fassett of Cooley LLP, at (720) 566-4025 or Ryan Lewis of Cooley LLP at (720) 556- 4187.
Sincerely,
Miragen Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Document
Miragen Therapeutics, Inc.
6200 Lookout Road
Boulder, CO 80301
(720) 643-5200
December 21, 2020
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Abby Adams
Re: Miragen Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-251367
Acceleration Request
Requested Date: Tuesday, December 22, 2020
Requested Time: 4:01 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Miragen Therapeutics, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to December 22, 2020, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Brent Fassett of Cooley LLP, at (720) 566-4025 or Ryan Lewis of Cooley LLP at (720) 556- 4187.
Sincerely,
Miragen Therapeutics, Inc.
By: /s/ Jason A. Leverone
Jason A. Leverone
Chief Financial Officer
cc: Lee Rauch, Miragen Therapeutics, Inc.
Brent D. Fassett, Esq., Cooley LLP
Ryan Lewis, Esq., Cooley LLP